[Form 4] PMV Pharmaceuticals, Inc Insider Trading Activity
PMV Pharmaceuticals (PMVP) 鈥� Form 4 insider transaction
Chief Financial Officer Michael Carulli disclosed the sale of 28,249 common shares on 01 July 2025 at a weighted-average price of $1.0647 per share. According to the filing, the disposition was made solely to satisfy tax-withholding obligations triggered by the vesting of restricted stock units (RSUs). After the transaction, the executive continues to beneficially own 60,146 shares of PMVP common stock, and no derivative security activity was reported. The sale represents a cash value of roughly $30,000 and leaves the CFO with a meaningful equity stake, limiting the signaling impact for investors.
PMV Pharmaceuticals (PMVP) 鈥� Transazione interna Form 4
Il Chief Financial Officer Michael Carulli ha comunicato la vendita di 28.249 azioni ordinarie il 1掳 luglio 2025 a un prezzo medio ponderato di 1,0647 $ per azione. Secondo la documentazione, la cessione 猫 stata effettuata esclusivamente per soddisfare gli obblighi fiscali derivanti dalla maturazione delle restricted stock units (RSU). Dopo l鈥檕perazione, il dirigente continua a possedere beneficiariamente 60.146 azioni ordinarie di PMVP, senza alcuna attivit脿 su strumenti derivati segnalata. La vendita rappresenta un valore in contanti di circa 30.000 $ e lascia al CFO una partecipazione azionaria significativa, limitando l鈥檌mpatto sul segnale per gli investitori.
PMV Pharmaceuticals (PMVP) 鈥� Transacci贸n interna Formulario 4
El Director Financiero Michael Carulli inform贸 la venta de 28,249 acciones ordinarias el 1 de julio de 2025 a un precio promedio ponderado de $1.0647 por acci贸n. Seg煤n el informe, la disposici贸n se realiz贸 煤nicamente para cumplir con las obligaciones fiscales derivadas de la consolidaci贸n de unidades de acciones restringidas (RSU). Tras la transacci贸n, el ejecutivo sigue poseyendo beneficiosamente 60,146 acciones ordinarias de PMVP, sin reportar actividad en valores derivados. La venta representa un valor en efectivo de aproximadamente $30,000 y mantiene al CFO con una participaci贸n accionaria significativa, limitando el impacto en la se帽al para los inversores.
PMV 鞝滌暯須岇偓(PMVP) 鈥� Form 4 雮措秬鞛� 瓯半灅
斓滉碃鞛毂呾瀯鞛� 毵堨澊韥� 旃措０毽皜 2025雲� 7鞗� 1鞚检棎 28,249欤� 氤错喌欤� 毵り皝 靷嫟鞚� 瓿奠嫓頄堨溂氅�, 欤茧嫻 臧�欷戫弶攴� 臧�瓴╈潃 $1.0647鞓�鞀惦媹雼�. 鞝滌稖 靹滊鞐� 霐半ゴ氅�, 鞚措矆 觳橂秳鞚� 鞝滍暅 欤检嫕 雼渼(RSU)鞚� 甓岆Μ 頇曥爼鞙茧 氚滌儩頃� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暅 氇╈爜鞚挫棃鞀惦媹雼�. 瓯半灅 頉� 頃措嫻 鞛勳洂鞚� PMVP 氤错喌欤� 60,146欤茧ゼ 瓿勳啀頃挫劀 鞁れ 靻岇湢頃橁碃 鞛堨溂氅�, 韺岇儩靸來拡 甏�霠� 頇滊彊鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 鞚措矆 毵り皝鞚� 鞎� $30,000鞚� 順勱笀 臧�旃橂ゼ 雮橅儉雮措┌, CFO臧� 鞚橂 鞛堧姅 歆�攵勳潉 鞙犾頃橃棳 韴瀽鞛愲摛鞐愱矊 氙胳箻電� 鞁犿樃 須臣毳� 鞝滍暅頃╇媹雼�.
PMV Pharmaceuticals (PMVP) 鈥� Transaction d鈥檌niti茅 Formulaire 4
Le directeur financier Michael Carulli a d茅clar茅 la vente de 28 249 actions ordinaires le 1er juillet 2025, 脿 un prix moyen pond茅r茅 de 1,0647 $ par action. Selon le d茅p么t, cette cession a 茅t茅 r茅alis茅e uniquement pour satisfaire aux obligations fiscales li茅es 脿 l鈥檃cquisition des unit茅s d鈥檃ctions restreintes (RSU). Apr猫s la transaction, le dirigeant continue de d茅tenir b茅n茅ficiairement 60 146 actions ordinaires de PMVP, sans activit茅 sur instruments d茅riv茅s signal茅e. Cette vente repr茅sente une valeur en liquidit茅s d鈥檈nviron 30 000 $ et laisse au CFO une participation significative, limitant ainsi l鈥檌mpact sur le signal envoy茅 aux investisseurs.
PMV Pharmaceuticals (PMVP) 鈥� Insider-Transaktion Form 4
Finanzvorstand Michael Carulli meldete den Verkauf von 28.249 Stammaktien am 1. Juli 2025 zu einem gewichteten Durchschnittspreis von 1,0647 $ pro Aktie. Laut der Meldung erfolgte die Ver盲u脽erung ausschlie脽lich zur Erf眉llung von Steuerabzugsverpflichtungen, die durch die Vesting von Restricted Stock Units (RSUs) ausgel枚st wurden. Nach der Transaktion besitzt der Gesch盲ftsf眉hrer weiterhin 60.146 Stammaktien von PMVP, und es wurden keine Derivateaktivit盲ten gemeldet. Der Verkauf entspricht einem Barwert von etwa 30.000 $ und l盲sst den CFO mit einer bedeutenden Beteiligung zur眉ck, wodurch die Signalwirkung f眉r Investoren begrenzt wird.
- Sale attributed to tax-withholding, suggesting no discretionary reduction in exposure.
- 60,146 shares remain under the CFO鈥檚 direct ownership, maintaining alignment with shareholders.
- Insider sale by a senior officer can be perceived as a modest negative signal despite its routine nature.
Insights
TL;DR: Routine tax-related sale; negligible governance signal.
The filing shows a standard RSU tax-withholding sale. Volume (28,249 shares) and value (~$30k) are immaterial versus typical insider trading thresholds, and the executive retains over 60k shares. Because the disposition is non-discretionary, it carries little informational content regarding the CFO鈥檚 outlook. I view the governance impact as neutral.
TL;DR: Small insider sale; limited market impact expected.
From a market perspective, the sale equals roughly one trading day鈥檚 volume for many micro-cap stocks and appears administrative. With no accompanying derivative transactions or changes in option holdings, the event does not alter the investment thesis. I classify the filing as not impactful for valuation or liquidity.
PMV Pharmaceuticals (PMVP) 鈥� Transazione interna Form 4
Il Chief Financial Officer Michael Carulli ha comunicato la vendita di 28.249 azioni ordinarie il 1掳 luglio 2025 a un prezzo medio ponderato di 1,0647 $ per azione. Secondo la documentazione, la cessione 猫 stata effettuata esclusivamente per soddisfare gli obblighi fiscali derivanti dalla maturazione delle restricted stock units (RSU). Dopo l鈥檕perazione, il dirigente continua a possedere beneficiariamente 60.146 azioni ordinarie di PMVP, senza alcuna attivit脿 su strumenti derivati segnalata. La vendita rappresenta un valore in contanti di circa 30.000 $ e lascia al CFO una partecipazione azionaria significativa, limitando l鈥檌mpatto sul segnale per gli investitori.
PMV Pharmaceuticals (PMVP) 鈥� Transacci贸n interna Formulario 4
El Director Financiero Michael Carulli inform贸 la venta de 28,249 acciones ordinarias el 1 de julio de 2025 a un precio promedio ponderado de $1.0647 por acci贸n. Seg煤n el informe, la disposici贸n se realiz贸 煤nicamente para cumplir con las obligaciones fiscales derivadas de la consolidaci贸n de unidades de acciones restringidas (RSU). Tras la transacci贸n, el ejecutivo sigue poseyendo beneficiosamente 60,146 acciones ordinarias de PMVP, sin reportar actividad en valores derivados. La venta representa un valor en efectivo de aproximadamente $30,000 y mantiene al CFO con una participaci贸n accionaria significativa, limitando el impacto en la se帽al para los inversores.
PMV 鞝滌暯須岇偓(PMVP) 鈥� Form 4 雮措秬鞛� 瓯半灅
斓滉碃鞛毂呾瀯鞛� 毵堨澊韥� 旃措０毽皜 2025雲� 7鞗� 1鞚检棎 28,249欤� 氤错喌欤� 毵り皝 靷嫟鞚� 瓿奠嫓頄堨溂氅�, 欤茧嫻 臧�欷戫弶攴� 臧�瓴╈潃 $1.0647鞓�鞀惦媹雼�. 鞝滌稖 靹滊鞐� 霐半ゴ氅�, 鞚措矆 觳橂秳鞚� 鞝滍暅 欤检嫕 雼渼(RSU)鞚� 甓岆Μ 頇曥爼鞙茧 氚滌儩頃� 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暅 氇╈爜鞚挫棃鞀惦媹雼�. 瓯半灅 頉� 頃措嫻 鞛勳洂鞚� PMVP 氤错喌欤� 60,146欤茧ゼ 瓿勳啀頃挫劀 鞁れ 靻岇湢頃橁碃 鞛堨溂氅�, 韺岇儩靸來拡 甏�霠� 頇滊彊鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 鞚措矆 毵り皝鞚� 鞎� $30,000鞚� 順勱笀 臧�旃橂ゼ 雮橅儉雮措┌, CFO臧� 鞚橂 鞛堧姅 歆�攵勳潉 鞙犾頃橃棳 韴瀽鞛愲摛鞐愱矊 氙胳箻電� 鞁犿樃 須臣毳� 鞝滍暅頃╇媹雼�.
PMV Pharmaceuticals (PMVP) 鈥� Transaction d鈥檌niti茅 Formulaire 4
Le directeur financier Michael Carulli a d茅clar茅 la vente de 28 249 actions ordinaires le 1er juillet 2025, 脿 un prix moyen pond茅r茅 de 1,0647 $ par action. Selon le d茅p么t, cette cession a 茅t茅 r茅alis茅e uniquement pour satisfaire aux obligations fiscales li茅es 脿 l鈥檃cquisition des unit茅s d鈥檃ctions restreintes (RSU). Apr猫s la transaction, le dirigeant continue de d茅tenir b茅n茅ficiairement 60 146 actions ordinaires de PMVP, sans activit茅 sur instruments d茅riv茅s signal茅e. Cette vente repr茅sente une valeur en liquidit茅s d鈥檈nviron 30 000 $ et laisse au CFO une participation significative, limitant ainsi l鈥檌mpact sur le signal envoy茅 aux investisseurs.
PMV Pharmaceuticals (PMVP) 鈥� Insider-Transaktion Form 4
Finanzvorstand Michael Carulli meldete den Verkauf von 28.249 Stammaktien am 1. Juli 2025 zu einem gewichteten Durchschnittspreis von 1,0647 $ pro Aktie. Laut der Meldung erfolgte die Ver盲u脽erung ausschlie脽lich zur Erf眉llung von Steuerabzugsverpflichtungen, die durch die Vesting von Restricted Stock Units (RSUs) ausgel枚st wurden. Nach der Transaktion besitzt der Gesch盲ftsf眉hrer weiterhin 60.146 Stammaktien von PMVP, und es wurden keine Derivateaktivit盲ten gemeldet. Der Verkauf entspricht einem Barwert von etwa 30.000 $ und l盲sst den CFO mit einer bedeutenden Beteiligung zur眉ck, wodurch die Signalwirkung f眉r Investoren begrenzt wird.
FAQ
What type of transaction did PMVP report on the Form 4?
How many PMVP shares were sold and at what price?
Why were the shares sold?
How many shares does the CFO own after the transaction?
Were any derivative securities involved in this filing?
